Timeliness of antiretroviral therapy initiation in the era before universal treatment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 05 2021
18 05 2021
Historique:
received:
02
08
2020
accepted:
06
05
2021
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
29
10
2021
Statut:
epublish
Résumé
We assessed the prevalence and factors related to the time to antiretroviral (ART) initiation among persons who entered HIV care and subsequently started ART in Croatia from 2005 to 2014. Included were patients ≥ 18 years, the follow-up ended on Dec/31/2017. 628 patients were included into the study 91.9% were men; median age was 36.1 (Q1-Q3: 29.6-43.8) years. Rapid (within 7 days of diagnosis) ART initiation was observed in 21.8% patients, 49.8% initiated ART within 30 days, 21.7% and 28.5% had intermediate (31 days-1 year) and late initiation (> 1 year), respectively. Of 608 patients that achieved an undetectable viral load, 94% had a plasma HIV-1 RNA < 50 copies/ml at last measurement after a median follow-up of 5.2 years. On quantile regression analysis, calendar year of entry into care, and markers of more advanced HIV disease (higher viral load, lower CD4 cell count and clinical AIDS) were significantly associated with earlier ART initiation. Early ART was not related to a gap in care afterwards at all quantiles. In conclusion, a significant proportion of patients started ART early in Croatia in 2005-2014. Early ART initiation led to durable viral load suppression and was not associated with a subsequent gap in care.
Identifiants
pubmed: 34006927
doi: 10.1038/s41598-021-90043-7
pii: 10.1038/s41598-021-90043-7
pmc: PMC8131373
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10508Références
Lancet HIV. 2016 Nov;3(11):e539-e548
pubmed: 27658873
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
AIDS Res Hum Retroviruses. 2013 Feb;29(2):329-36
pubmed: 22906365
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
HIV Med. 2019 Nov;20(10):699-703
pubmed: 31424598
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
HIV Med. 2019 Mar;20 Suppl 1:3-11
pubmed: 30724450
Clin Infect Dis. 2018 Feb 10;66(5):727-734
pubmed: 29069362
AIDS Behav. 2008 Jul;12(4 Suppl):S48-53
pubmed: 18459042
PLoS One. 2019 Jan 4;14(1):e0210096
pubmed: 30608962
Sci Rep. 2019 Nov 21;9(1):17307
pubmed: 31754119
BMJ Open. 2019 Sep 20;9(9):e033246
pubmed: 31542770
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
J Infect Dis. 2019 Jul 19;220(4):648-656
pubmed: 30997508
N Engl J Med. 2009 Apr 30;360(18):1815-26
pubmed: 19339714
Glob Health Action. 2018;11(1):1520473
pubmed: 30499382
J Infect Dis. 2020 Aug 4;222(5):755-764
pubmed: 31682261
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):65-73
pubmed: 28542080
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
J Manag Care Spec Pharm. 2020 Feb;26(2):129-141
pubmed: 31747358
AIDS. 2019 Apr 1;33(5):825-832
pubmed: 30882490
PLoS One. 2017 May 16;12(5):e0177634
pubmed: 28520807
Clin Infect Dis. 2020 Jul 11;71(2):293-300
pubmed: 31612225
PLoS Med. 2017 Nov 14;14(11):e1002433
pubmed: 29136001
Coll Antropol. 2006 Dec;30 Suppl 2:17-23
pubmed: 17508469
PLoS One. 2010 Nov 24;5(11):e15051
pubmed: 21124844
Clin Infect Dis. 2020 Dec 31;:
pubmed: 33383586
BMC Public Health. 2013 May 21;13:490
pubmed: 23687946
Lancet HIV. 2015 Aug;2(8):e335-43
pubmed: 26423376
Cochrane Database Syst Rev. 2019 Jun 17;6:CD012962
pubmed: 31206168
PLoS One. 2019 Sep 6;14(9):e0222067
pubmed: 31490985
PLoS Med. 2017 Nov 7;14(11):e1002420
pubmed: 29112963